Delivery Order SPE2DB20D1100-SPE2DB25FE6Q5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,667.86 to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 ml auto-injector supplies. This firm fixed-price, non-set-aside contract was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a continuation of the vendor's extensive...
- The Defense Logistics Agency awarded a delivery order valued at $1,372.49 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units. This is a firm fixed price, competitively awarded contract with no set-aside designation, completed on August 19, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's place of performance for this federal procurement. This...
- The Defense Logistics Agency awarded a $2,150.75 delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency awarded a delivery order valued at $1,629.66 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector units. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of September 15, 2025. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector vials valued at $3,609.99 with completion targeted for August 19, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed price terms and is performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,188.98 on July 22, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 23, 2025, and performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,388.60 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector (0.5 ml). This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 ml auto-injector units, valued at $2,353.38. This was a competitively awarded, firm fixed-price delivery order with an ultimate completion date of August 5, 2025. The contract contains no set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE6Q5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,086.44 to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies, with an ultimate completion date of September 15, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and is being fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. Through this prime contract vehicle, AmerisourceBergen supplies a broad range of pharmaceutical products and medical commodities to support military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities. The company's consistent receipt of competitive delivery orders across multiple therapeutic domains demonstrates its established capability to meet federal medical supply requirements at scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/12/25 |